AI
Friday, September 24, 2021 11:16:40 AM
<< Any idea of the $25-$30k figure is reasonable? >>
That it is a very reasonable estimate.
Biogen’s Aduhelm costs about $56K per year & Eli Lilly’s Donanemab @ $50K per year.
A recent Seeking Alpha article gave an estimated price of $28K per year for Simufilam. That estimated price was a blended average of 3 estimates that have been made by analysts over the past few months:
- $20K from B Riley Securities (made on 3 Aug)
- $25K from Maxim Group (made on 7 Jul)
- $40K from Jones Trading (made on 28 Jun)
That it is a very reasonable estimate.
Biogen’s Aduhelm costs about $56K per year & Eli Lilly’s Donanemab @ $50K per year.
A recent Seeking Alpha article gave an estimated price of $28K per year for Simufilam. That estimated price was a blended average of 3 estimates that have been made by analysts over the past few months:
- $20K from B Riley Securities (made on 3 Aug)
- $25K from Maxim Group (made on 7 Jul)
- $40K from Jones Trading (made on 28 Jun)
